ASL perfusion radiomic heterogeneity is associated with early mortality in IDH-wildtype glioblastoma, beyond tumor volume: a time-varying effect with tumor-aware DTI-ALPS - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Radiomic Heterogeneity of ASL Perfusion Correlates with Early Mortality in IDH-Wildtype Glioblastoma, Independent of Tumor Volume: Insights from Time-Varying Effects Using Tumor-Aware DTI-ALPS

  • By

  • Rafail C. Christodoulou

  • Georgios Vamvouras

  • Platon S. Papageorgiou

  • Evros Vassiliou

  • Elena E. Solomou

  • Sokratis G. Papageorgiou

  • Michalis F. Georgiou

  • September 9, 2026

Share

  • 1

    ASL perfusion heterogeneity is associated with early mortality in IDH-wildtype glioblastoma, independent of tumor volume and clinical variables.

  • 2

    The study analyzed 322 patients with IDH-wildtype WHO grade 4 glioblastoma using volume-adjusted Cox proportional hazards models.

  • 3

    Mortality within 365 days correlated with greater ASL heterogeneity, with hazard ratios indicating significant associations after adjustments.

  • 4

    DTI-ALPS did not enhance classifier performance or show independent prognostic value in relation to survival outcomes.

  • 5

    Findings suggest the necessity for volume-adjusted testing in radiomics research, as tumor volume significantly influenced overall survival results.

Original Source(s)

ASL perfusion radiomic heterogeneity is associated with early mortality in IDH-wildtype glioblastoma, beyond tumor volume: a time-varying effect with tumor-aware DTI-ALPS

  • by Rafail C. Christodoulou, Georgios Vamvouras, Platon S. Papageorgiou, Evros Vassiliou, Elena E. Solomou, Sokratis G. Papageorgiou, Michalis F. Georgiou

  • September 9, 2026

Related Content

Physical exercise in brain tumor patients: a systematic review

CAR T Before Surgery Improves Glioblastoma Control in Mice

Study finds that tumor resection creates a more immunosuppressive environment and that earlier CAR T cell treatment prolongs survival

  • September 7, 2026

  • 3 min
Editorial: Tumor microenvironment and personalized therapy of gastrointestinal cancer Ⅱ